Completion of sanofi-aventis acquisition of Merck’s 50 percent interest in Merial (Form 8-K, Exhibit 99.1) (2009)

Government Record · Sanofi-aventis and Merck & Co., Inc. · September 18, 2009

Sanofi-aventis et al., 2009-09-18: Merck's 8-K exhibit announcing that sanofi-aventis completed its acquisition of Merck's 50 percent interest in Merial, making Merial a wholly owned sanofi-aventis subsidiary in 2009.

Formed in 1997, Merial is a leading animal health company that was a 50/50 joint venture between Merck and sanofi-aventis and is now a wholly-owned subsidiary of sanofi-aventis.

Sanofi-aventis et al., 2009-09-18: Merck's 8-K exhibit announcing that sanofi-aventis completed its acquisition of Merck's 50 percent interest in Merial, making Merial a wholly owned sanofi-aventis subsidiary in 2009. C8 (animal brands). Same document as the F4 row (dedupe on claim+URL keeps both). Ownership chain, neutral disclosure: Merck sold its 50% of Merial for $4 billion in cash; Sanofi then held Ivomec/Heartgard outright until the 2017 swap with Boehringer Ingelheim. No statement about prices or conduct is implied. Also filed as IVB-46 (claims C8, F4).